PUNE, India, September 8, 2016 /PRNewswire/ --
RnRMarketResearch.com adds a new report on pain management market that discusses a number of novel delivery technologies employed in the formulating abuse deterrent product, technologies employed in enhancing patient compliances, emerging novel mechanisms and late stage pipeline drugs in the management of pain.
Complete report on Pain Management Market spreads across 135 pages, analysing 79 major companies and provides 12 data tables and 40 Charts is now available at http://www.rnrmarketresearch.com/pain-management-new-discoveries-and-treatment-options-in-abuse-deterrent-era-o-opioids-novel-abuse-deterrent-formulation-technologies-pipeline-drugs-o-emerging-novel-technologies-mechanisms-and-late-stage-nt-of-pain-market-report.html .
The Rescheduling of Hydrocodone combinations from Class III to Class II, clear-cut regulatory guideline for Abuse Deterrent drug formulation NDA & ANDA (solid oral) filing and CDC guideline for Prescribing Opioids for Chronic Pain (2016) are definite steps taken by FDA in last two years for creating "Abuse Deterrent Era" in a short span to stop opioid abuse and reversing opioid epidemic in USA. There were around 18,893 deaths involving prescription of opioids in the United States in 2014 which was up 16% from 2013 as per NCHS (National Center for Health Statistics).
Around +6 plus extended release abuse deterrent formulations with Abuse deterrent (AD) labels are approved in last two years (Xtampza ER, MorphaBond ER, Hysingla ER, Embeda ER, Targiniq ER, Oxaydo) and are expected to provide improvements over existing formulations for abuse deterrent purpose. But they have some limitation for restricting abuse mainly through oral intake- swallowing a number of intact tablets or capsules. Despite, Extended release (ER) Abuse Deterrent Formulations partly control Opioids abuse (through nasal or injection routes), ER opioids has high potential of abuse, its AD formulation add significant value to create "Abuse Deterrent Era" in the coming time.
Around 20 plus Abuse Deterrent Formulations of opioids are in the pipeline and most of them are ER formulations which use different AD tech platform to make its ADF. Amongst these pipeline ADF drugs, 6 are of Hydrocodone, 8 are of Morphine and 6 are of Oxycodone based ADF formulations. New NCEs targeting Opioids receptor are in pipeline which reduces Opioids abuse by its MoA (slow rate of entry in Brain) and may have potential to deal with reducing opioid abuse through restricting oral intake in coming years.
US Opioids market is of $8b in size and of which extended release formulations contribute 50%. ADF ER formulations and its generic versions & New NCEs targeting Opioid receptor will drive the growth of opioid market in US and Europe in coming years.
Order a Copy of Report at http://www.rnrmarketresearch.com/contacts/purchase?rname=684824.
Late stage NCE pipeline drugs (Cebranopadol, Mirogabalin, NKT-181, AVP-923,...) and Novel technologies targeting formulation change in old generic drugs (ORB-201, OX-51, ARX-04,CL-108, once daily Pregabalin..) for pain management has potential to reduce opioids use in future to treat pain. While TRKA receptor antagonist, NAV1.7 sodium channel modulator inhibitor and angiotension II antagonist are few new MoA which has promising drug in clinical development for moderate to severe pain management.
Companies mentioned are in the Pain Management Market New Discoveries and Treatment Options in Abuse Deterrent Era • Opioids - Novel Abuse deterrent Formulation Technologies & Pipeline drugs • Emerging Novel Technologies, Mechanisms and late stage pipeline drugs in the Management of Pain report are:
AbbVie, AcelRx pharma, Acorda Therapeutics, Actavis, Acura Pharma, Acorda Therapeutics, Altus formulations, Alkermes, Algiax Pharmaceuticals, Amorsa Therapeutics, AnGes, AstraZeneca, Balerna, Biogen, BioDelivery Sciences International Inc, Biopharma, Cara Therapeutics, Catalent, Charleston, Celltech, Collegium Pharma, Convergence, Columbia Labs, Convatech, Daiichi Sankyo, Daewoong, Depomed, Durect, Egalet, Eli Lilly, Elite Pharma, Endo, Ensyce Bioscience, EpiCept, Flamel Technologies, Flexion Therapeutics, Forest, Glenmark, Grunenthal, GlaxoSmithKline, GW Pharma, Immune Pharmaceuticals, Impax Pharmaceuticals, Inspirion, Intelli Pharmaceutics, IRX Therapeutics, Johnson and Johnson, KemPharm, Kineta, Kunwha Pharmaceutical, Medallion Therapeutics, Mallinckrodt, Nektar, Novartis, Noven, Orbis Biosciences and more.
Another related report is Global Pain Management Drugs Market 2016 - 2020: analysts forecast global pain management drugs market to grow at a CAGR of 4.97% during the period 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs that are used for the management of pain. Complete report available at http://www.rnrmarketresearch.com/global-pain-management-drugs-market-2016-2020-market-report.html.
Explore other reports on pain management market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/pain-management.
About Us:
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
Tel: +1-888-391-5441
sales@rnrmarketresearch.com
Connect with Us:
G+ / Google Plus: https://plus.google.com/104156468549256253075/posts
Twitter: https://twitter.com/RnRMR
Facebook: https://www.facebook.com/pages/RnR-Market-Research/413488545356345
RSS / Feeds: http://www.rnrmarketresearch.com/feed
